Search

This study aims to investigate the antitumor activity and safety of a HER2-targeted antibody-drug conjugate, RC48-ADC, intravesical instillation for NMIBC treatment." According to the news editors, the research concluded: "These preclinical findings provide evidence to support further clinical trials of intravesical RC48-ADC in patients with non-muscle-invasive bladder cancer to improve therapeutic outcome.image." Keywords: Guangdong; People's Republic of China; Asia; Antibodies; Bladder Cancer; Blood Proteins; Cancer; Clinical Research; Clinical Trials and Studies; Drug Conjugates; Drug Development; Drugs and Therapies; Health and Medicine; Immunoglobulins; Immunology; Intravesical Administration; Oncology; Pre-Trial Research; Proteins; Therapeutics; Therapy; Topical Administration EN Guangdong People's Republic of China Asia Antibodies Bladder Cancer Blood Proteins Cancer Clinical Research Clinical Trials and Studies Drug Conjugates Drug Development Drugs and Therapies Health and Medicine Immunoglobulins Immunology Intravesical Administration Oncology Pre-Trial Research Proteins Therapeutics Therapy Topical Administration 1534 1534 1 11/06/23 20231106 NES 231106 2023 NOV 7 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Oncology - Bladder Cancer are discussed in a new report. [Extracted from the article]